Also, I note that through all the presentations after the halt, it never seemed like that was a complete disaster from the researcher's points of view or even the company. They thought about lifting it, and it's not entirely clear the reasons for it to us, though I suspect that the FDA was protecting the placebo arm in a cross-over trial, and of course, I could be wrong.
The rGBM trial with DCVax and checkpoint inhibitor, on clinicaltrials.gov certainly indicates something positive to me as well, particularly the small nature of that trial.